Clinical Trial

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Study acronym: ziMyG+
Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the long-term safety and tolerability of an additional 52 weeks of Zilucoplan treatment administered by subcutaneous injection once daily in pediatric study participants
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2024-05-23; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-12-02
Trial Details
NCT Number NCT06435312
Lead Sponsor UCB Biopharma SRL
Conditions Generalized Myasthenia Gravis
Enrollment 8 participants
Start Date 2024-11-19
Primary Completion 2027-10-26 (estimated)
Study Completion 2027-11-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-31